Immutep Ltd ADR (IMMP)

2.140
-0.100(-4.46%)
After Hours
2.140
0.000(0.00%)
- Real-time Data
  • Volume:
    129,470
  • Day's Range:
    2.050 - 2.230
  • 52 wk Range:
    1.850 - 5.000
Earnings results expected in 12 days

IMMP Overview

Prev. Close
2.24
Day's Range
2.05-2.23
Revenue
-
Open
2.19
52 wk Range
1.85-5
EPS
-
Volume
129,470
Market Cap
188.9M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
102,813
P/E Ratio
-
Beta
-
1-Year Change
-34.76%
Shares Outstanding
866,239,815
Next Earnings Date
Aug 30, 2022
What is your sentiment on Immutep ADR?
or
Market is currently closed. Voting is open during market hours.

Immutep Ltd ADR News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Immutep Ltd ADR Analysis

Immutep Ltd ADR Company Profile

Immutep Ltd ADR Company Profile

Employees
0

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • IMMP's Eftilagimod Alpha advances to Phase II study in COVID-19 patients, 6 of whom have already been discharged from hospital after taking injections of efti alpha.
    0
    • any news ?? soon
      0
      • this supposed to go up ,it was news about progress of clinical trials
        0
        • At least 5$ this month.
          0
        • hopefully
          0
      • IMMUTEP secured US patent for cancer drug. Stock jumps 15%. Will go further up in coming months.
        0
        • "IMMP is planning to increase the efti manufacturing process from 200L to 2000L capacity bioreactors at the Wuxi Biologics manufacturing plant with major scale up steps taking place throughout 2021"
          0
          • so what? -8%
            0
          • EL KAT It'll shoot up soon. Momentum's been building up nicely.
            0
        • l think this is going nowhere 😕
          1
          • lol consolidation should be be done soon .
            0
            • delayed reaction on today's news . READ !
              0
              • analyst are underestimate target price by a long shot ! more news could be coming as early as today!
                0
                • more news about ??
                  0
              • big boys kept their wallets full . hope it goes up 2 bucks over night
                0